Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate to severe psoriasis treated with guselkumab: 3-year data from VOYAGE 1 - 22/08/19
Andrew Blauvelt, MD, Oregon Medical Research Center, Portland, OR; Chenglong Han, PhD, Janssen Research & Development, LLC, Spring House, PA; Kim A. Papp, MD, K Papp Clinical Research and Probity Medical Research Inc, Waterloo, Ontario, Canada; Christopher E.M. Griffiths, MD, Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester, UK; Pablo Fernandez-Penas, MD, The University of Sydney and Westmead Hospital, Sydney, Australia; David N. Adam, MD, University of Toronto and Probity Medical Research, Ajax, Ontario, Canada; Sandra Philipp, MD, Dermatology, Charité, Universitaetsmedizin Berlin, Berlin, Germany; Michael Song, MD, Janssen Research & Development, LLC, Spring House, PA; Yaung-Kaung Shen, PhD, Janssen Research & Development, LLC, Spring House, PA; Alexa B. Kimball, MD, Harvard Medical School, Boston, MA
Le texte complet de cet article est disponible en PDF.| Supported 100% by Janssen Research & Development, LLC. |
Vol 81 - N° 4S1
P. AB165 - octobre 2019 Retour au numéro
Article précédent
- Absolute PASI and secukinumab in plaque psoriasis: Experience of clinical practice in a tertiary Hospital of Valencia, Spain
- Acne vulgaris is associated with serious infections in a United States inpatient population
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?